Long-Acting Cabotegravir for HIV Prevention: Issues of Access, Cost, and Equity

JAMA. 2022 Mar 8;327(10):921-922. doi: 10.1001/jama.2022.0420.

Authors

Joshua M Sharfstein¹, Amy Killelea², Derek Dangerfield³

Affiliations

¹ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Killelea Consulting, Arlington, Virginia.
³ Johns Hopkins School of Nursing, Baltimore, Maryland.

PMID: 35157006
DOI: 10.1001/jama.2022.0420

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Costs and Cost Analysis
Diketopiperazines / economics
Diketopiperazines / therapeutic use*
HIV Infections / prevention & control*
HIV Integrase Inhibitors / economics
HIV Integrase Inhibitors / therapeutic use*
Health Equity
Health Services Accessibility
Humans
Pyridones / economics
Pyridones / therapeutic use*

Substances

Diketopiperazines
HIV Integrase Inhibitors
Pyridones
cabotegravir